title: Vaginal retention of locally administered clindamycin.
abstract: Since bacterial vaginosis (BV) is characterized by a lack of, or very few, lactobacilli and high numbers of small, mostly anaerobic bacteria, an obvious treatment modality would be eradication of the BV-associated bacterial flora followed by reintroduction of lactobacilli vaginally. As probiotic treatment with lactobacilli is one tool for improving the cure rate when treating BV, it is necessary to know the length of time after treatment that clindamycin can be found in the vagina and if this could interfere with the growth of the probiotic lactobacilli. We evaluated the vaginal concentration of clindamycin in 12 women for 8 days to obtain data on the concentration of clindamycin in the vagina after intravaginal treatment with the drug. The participants were examined five times between two menstrual periods: before treatment, the day after treatment was finished, and 3, 5 and 8 days post-treatment. The first day post-treatment clindamycin 0.46 × 10(-3) to 8.4 × 10(-3) g/g vaginal fluid (median 2.87 × 10(-3)) was found. Thereafter, the concentration of clindamycin decreased rapidly. In 10 patients clindamycin was found after 3 days. A very low concentration was still present 5 days after treatment in four patients. After 8 days no clindamycin was found. Clindamycin is rapidly eliminated from the vagina, within 3-8 days, after local administration. Our results indicate that treatment with probiotic lactobacilli could be problematic if carried out within 5 days after cessation of clindamycin treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Ålands Centralsjukhus, Mariehamn, Finland. katarina.eriksson@aland.net
authors.forename: Katarina
authors.initials: K
authors.lastname: Eriksson
authors.forename: Per-Göran
authors.initials: PG
authors.lastname: Larsson
authors.forename: Maud
authors.initials: M
authors.lastname: Nilsson
authors.forename: Urban
authors.initials: U
authors.lastname: Forsum
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002981:Clindamycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007778:Lactobacillus / Q000254:growth & development / Q000378:metabolism; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage; D011446:Prospective Studies; D016896:Treatment Outcome; D014621:Vagina / Q000382:microbiology* / Q000473:pathology*; D016585:Vaginosis, Bacterial / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin